{"id":"https://openalex.org/W4386594281","doi":"https://doi.org/10.1002/cpt.3046","title":"Population Pharmacokinetics and Pharmacodynamics of Pegozafermin in Patients with Nonalcoholic Steatohepatitis","display_name":"Population Pharmacokinetics and Pharmacodynamics of Pegozafermin in Patients with Nonalcoholic Steatohepatitis","publication_year":2023,"publication_date":"2023-09-12","ids":{"openalex":"https://openalex.org/W4386594281","doi":"https://doi.org/10.1002/cpt.3046","pmid":"https://pubmed.ncbi.nlm.nih.gov/37696614"},"language":"en","primary_location":{"id":"doi:10.1002/cpt.3046","doi":"https://doi.org/10.1002/cpt.3046","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cpt.3046","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology & Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111723106","display_name":"Chih-Ming L. Tseng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405273169","display_name":"89bio (United States)","ror":"https://ror.org/05cwkte76","country_code":"US","type":"company","lineage":["https://openalex.org/I4405273169"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Chih\u2010Ming Leo Tseng","raw_affiliation_strings":["Clinical Development, 89bio, Inc., San Francisco, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development, 89bio, Inc., San Francisco, California, USA","institution_ids":["https://openalex.org/I4405273169"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030794461","display_name":"Kemal Balic","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405273169","display_name":"89bio (United States)","ror":"https://ror.org/05cwkte76","country_code":"US","type":"company","lineage":["https://openalex.org/I4405273169"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kemal Balic","raw_affiliation_strings":["Clinical Development, 89bio, Inc., San Francisco, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development, 89bio, Inc., San Francisco, California, USA","institution_ids":["https://openalex.org/I4405273169"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061983367","display_name":"R. Will Charlton","orcid":"https://orcid.org/0000-0001-8451-9165","observed_orcids":["https://orcid.org/0000-0001-8451-9165"]},"institutions":[{"id":"https://openalex.org/I4405273169","display_name":"89bio (United States)","ror":"https://ror.org/05cwkte76","country_code":"US","type":"company","lineage":["https://openalex.org/I4405273169"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Will Charlton","raw_affiliation_strings":["Clinical Development, 89bio, Inc., San Francisco, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development, 89bio, Inc., San Francisco, California, USA","institution_ids":["https://openalex.org/I4405273169"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001719819","display_name":"Maya Margalit","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405273169","display_name":"89bio (United States)","ror":"https://ror.org/05cwkte76","country_code":"US","type":"company","lineage":["https://openalex.org/I4405273169"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maya Margalit","raw_affiliation_strings":["Clinical Development, 89bio, Inc., Herzliya, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development, 89bio, Inc., Herzliya, Israel","institution_ids":["https://openalex.org/I4405273169"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109731361","display_name":"Hank Mansbach","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405273169","display_name":"89bio (United States)","ror":"https://ror.org/05cwkte76","country_code":"US","type":"company","lineage":["https://openalex.org/I4405273169"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hank Mansbach","raw_affiliation_strings":["Clinical Development, 89bio, Inc., San Francisco, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development, 89bio, Inc., San Francisco, California, USA","institution_ids":["https://openalex.org/I4405273169"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5003508947","display_name":"Radojka M. Savi\u0107","orcid":"https://orcid.org/0000-0003-3143-5579","observed_orcids":["https://orcid.org/0000-0003-3143-5579","https://orcid.org/0009-0001-3093-9081"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rada M. Savic","raw_affiliation_strings":["Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA","institution_ids":["https://openalex.org/I180670191"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5111723106"],"corresponding_institution_ids":["https://openalex.org/I4405273169"],"apc_list":{"value":4000,"currency":"USD","value_usd":4000},"apc_paid":null,"fwci":0.8463,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":{"value":0.69877278,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":97},"biblio":{"volume":"114","issue":"6","first_page":"1323","last_page":"1331"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10351","display_name":"Liver Disease Diagnosis and Treatment","score":0.8407999873161316,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10351","display_name":"Liver Disease Diagnosis and Treatment","score":0.8407999873161316,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":0.07959999889135361,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.025800000876188278,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-alcoholic-steatohepatitis","display_name":"nonalcoholic steatohepatitis","score":0.9580000042915344},{"id":"https://openalex.org/keywords/fgf21","display_name":"FGF21","score":0.8790000081062317},{"id":"https://openalex.org/keywords/hepatic-fat-fraction","display_name":"hepatic fat fraction","score":0.953000009059906},{"id":"https://openalex.org/keywords/pharmacokinetic-pharmacodynamic-modeling","display_name":"pharmacokinetic-pharmacodynamic modeling","score":0.7749999761581421},{"id":"https://openalex.org/keywords/exposure-response-relationship","display_name":"exposure-response relationship","score":0.9300000071525574},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.6349999904632568},{"id":"https://openalex.org/keywords/dose-selection","display_name":"dose selection","score":0.7850000262260437},{"id":"https://openalex.org/keywords/fibrosis-regression","display_name":"fibrosis regression","score":0.7129999995231628},{"id":"https://openalex.org/keywords/alanine-aminotransferase","display_name":"alanine aminotransferase","score":0.8460000157356262},{"id":"https://openalex.org/keywords/liver-volume","display_name":"liver volume","score":0.7649999856948853},{"id":"https://openalex.org/keywords/body-weight","display_name":"body weight","score":0.6639999747276306}],"concepts":[{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.741981029510498},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7133374214172363},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6855688095092773},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6790055632591248},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5633136630058289},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5502066612243652},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.4835200309753418},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4799945056438446},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.45193493366241455},{"id":"https://openalex.org/C3018708256","wikidata":"https://www.wikidata.org/wiki/Q1546498","display_name":"Nonalcoholic steatohepatitis","level":5,"score":0.41357800364494324},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.17428478598594666},{"id":"https://openalex.org/C2778772119","wikidata":"https://www.wikidata.org/wiki/Q6058862","display_name":"Fatty liver","level":3,"score":0.09766817092895508},{"id":"https://openalex.org/C2776954865","wikidata":"https://www.wikidata.org/wiki/Q1546498","display_name":"Nonalcoholic fatty liver disease","level":4,"score":0.08533897995948792},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D001835","descriptor_name":"Body Weight","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065626","descriptor_name":"Non-alcoholic Fatty Liver Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1002/cpt.3046","doi":"https://doi.org/10.1002/cpt.3046","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cpt.3046","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology & Therapeutics","raw_type":"journal-article"},{"id":"pmid:37696614","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37696614","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology and therapeutics","raw_type":"Randomized Controlled Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W2062842771","https://openalex.org/W2100232436","https://openalex.org/W2168118376","https://openalex.org/W2204688218","https://openalex.org/W2252509418","https://openalex.org/W2620038295","https://openalex.org/W2784619339","https://openalex.org/W2791880774","https://openalex.org/W2806909958","https://openalex.org/W2903736473","https://openalex.org/W2905440332","https://openalex.org/W2922213148","https://openalex.org/W2947312239","https://openalex.org/W2984524859","https://openalex.org/W3022734346","https://openalex.org/W3044370932","https://openalex.org/W3086926714","https://openalex.org/W3097305945","https://openalex.org/W3111490933","https://openalex.org/W3113529260","https://openalex.org/W3154897461","https://openalex.org/W3182732609","https://openalex.org/W4311426185","https://openalex.org/W4381884589"],"related_works":["https://openalex.org/W4311426185","https://openalex.org/W4381884589","https://openalex.org/W4386817519","https://openalex.org/W4399704140","https://openalex.org/W4311426804","https://openalex.org/W4375946738","https://openalex.org/W4375946757","https://openalex.org/W4385261135","https://openalex.org/W4399704164","https://openalex.org/W6922664525"],"abstract_inverted_index":{"Pegozafermin":[0,111],"is":[1],"a":[2,25,53,117,193],"long-acting":[3],"glycoPEGylated":[4],"analog":[5],"of":[6,17,40,82,149,227],"fibroblast":[7],"growth":[8],"factor":[9],"21":[10],"(FGF21)":[11],"in":[12,34,43,47,237],"development":[13],"for":[14,108,219,232,245,248],"the":[15,63,85,96,177,183,225,243,249],"treatment":[16,235],"nonalcoholic":[18],"steatohepatitis":[19],"(NASH)":[20],"and":[21,56,69,78,93,171,229,241],"severe":[22],"hypertriglyceridemia.":[23],"In":[24],"phase":[26,86,250],"Ib/IIa":[27,87],"placebo-controlled,":[28],"double-blind,":[29],"multiple":[30],"ascending":[31],"dose":[32,106,181,246],"study":[33,88,253],"patients":[35,189,238],"with":[36,52,122,144,239],"NASH":[37],"(NCT04048135),":[38],"administration":[39],"pegozafermin":[41,66,138,146],"resulted":[42],"clinically":[44],"meaningful":[45],"reductions":[46],"hepatic":[48],"fat":[49],"fraction":[50],"(HFF),":[51],"favorable":[54,234],"safety":[55],"tolerability":[57],"profile.":[58],"We":[59,74],"aimed":[60],"to":[61,89,103,137,198,214],"characterize":[62],"relationship":[64],"between":[65],"dosing,":[67],"exposure":[68,112],"effects":[70],"on":[71],"HFF":[72,132,140,200,220],"reduction.":[73,221],"used":[75],"pharmacokinetic":[76],"(PK)":[77],"pharmacodynamic":[79],"(PD)":[80],"modeling":[81,129,223],"data":[83],"from":[84,192],"identify":[90],"model":[91,162],"parameters":[92],"covariates":[94,163],"affecting":[95],"exposure-response":[97],"relationship.":[98],"Clinical":[99],"simulations":[100],"were":[101,142],"performed":[102],"help":[104],"support":[105],"selection":[107,247],"larger":[109],"studies.":[110],"was":[113,134],"adequately":[114],"described":[115],"by":[116],"one":[118,123],"compartment":[119],"PK":[120],"model,":[121],"additional":[124],"transit":[125],"absorption":[126],"compartment.":[127],"PK/PD":[128,161],"demonstrated":[130],"that":[131,176],"reduction":[133],"significantly":[135],"related":[136],"exposure.":[139],"outcomes":[141,236],"correlated":[143],"average":[145],"concentrations":[147],"regardless":[148],"weekly":[150],"dosing":[151,154,209,231],"(q.w.)":[152],"or":[153,196],"every":[155],"2":[156],"weeks":[157],"(q2w).":[158],"The":[159],"significant":[160],"included":[164],"baseline":[165],"body":[166],"weight,":[167],"alanine":[168],"aminotransferase":[169],"level,":[170],"liver":[172],"volume.":[173],"Simulations":[174],"showed":[175],"30":[178],"mg":[179,207,211],"q.w.":[180,228],"approximated":[182],"full":[184],"PD":[185],"effect;":[186],"almost":[187],"all":[188],"would":[190],"benefit":[191],"greater":[194],"than":[195],"equal":[197],"30%":[199],"reduction,":[201],"suggesting":[202],"fibrosis":[203],"regression.":[204],"Furthermore,":[205],"44":[206],"q2w":[208,230],"(~22":[210],"q.w.)":[212],"appeared":[213],"be":[215],"an":[216],"effective":[217],"regimen":[218],"Our":[222],"supports":[224],"feasibility":[226],"achieving":[233],"NASH,":[240],"provides":[242],"rationale":[244],"IIb":[251],"ENLIVEN":[252],"(NCT04929483).":[254]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-09-12T00:00:00"}